Abstracts senting net savings of €1123 per patient. Using rhBMP-2 in all grades of tibia fracture resulted in an incremental cost of €134 per patient and a cost-effectiveness ratio of €3052/QALY. In France, using rhBMP-2 for grade III open tibia fractures, and all fractures resulted in cost savings of €2312, and €824 per patient, respectively. When analyzed from the NHS perspective in the UK, rhBMP-2 treatment for grade III open tibia fractures resulted in a cost-effectiveness ratio of €10,847 (GBP7445) per QALY and €32,151 (GBP22,066) per QALY for all types of fractures. CONCLUSIONS: From a payer's perspective, rhBMP-2 is a cost-saving treatment option in grade III open tibia fractures for the German and French health care systems and cost-effective for all grades of open tibia fractures in Germany, UK, and France.
POS5 AN ECONOMIC EVALUATION OF ZOLEDRONIC ACID TREATMENT IN PAGET'S DISEASE OF BONE IN THE HUNGARIAN HEALTH CARE SETTING
Kosa J Novartis Hungary Ltd, Budapest, Pest, Hungary Cost-effectiveness model was adopted to the Hungarian health care settings in order to evaluate the costs, effectiveness and costeffectiveness of two years comparison of zoledronic acid therapy (5 mg infusion over 15 minutes given once) with risedronate therapy (30 mg/day orally given for 2 months), alendronate therapy (40 mg/day orally given for 6 months), tiludronate therapy (400 mg/day orally given for 3 months) and pamidronate therapy (180 mg I.V. in 6 weeks) in patients with Paget's disease of bone. The long term outcome was evaluated by the cost per time in response over two years period. The measure of effect the time patients are in response was based on SAP measurement. Data sources were randomized clinical trials of treatments in PDB, literature and expert opinion. The analysis was performed from a society perspective. Discounting rate of 6% was applied for costs and effects in the second year. A standard costing methodology was used, according to the patterns of care currently in use in Hungary. Costs were calculated to cover medical procedures performed in two years time frame for patients with PDB and include direct costs of treatment and follow-up (visit to physicians offices, prescription of medication, laboratory procedures and treatment costs of side effects. As a result zoledronic acid dominated all the other therapies compared, hence it was the most effective and the least expensive in the treatment of Paget's disease of bone.
POS6 ECONOMIC ANALYSIS: IBANDRONATE (BONVIVA®) IV INJECTION FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS (PMO) IN THE UK
Cowell W 1 , Koay A 1 , Hunjan M 2 1 Roche Products Ltd, Welwyn Garden City, UK, 2 GlaxoSmithkline, Middlesex, UK OBJECTIVES: Oral bisphosphonate treatment is standard therapy for PMO, but certain patients are unsuitable for this therapy due to intolerance or dosing difficulties. Such patients may receive "off-label" unlicensed IV bisphosphonates, typically IV pamidronate in the UK. Ibandronate is the first IV preparation licensed for PMO and this study provides an economic analysis of IV ibandronate in this setting. METHODS: IV ibandronate is administered as a 3 mg IV "push" lasting 15-30 seconds every 3 months, and priced approximately £27/mg. IV pamidronate (30-60 mg) is infused (10-60 mg/hour) every 3 months, and priced at approximately £2/mg across the preparations available. A cost-minimisation analysis was undertaken to demonstrate the economic case for IV ibandronate, since based on a review of the clinical evidence base and licensing status, IV ibandronate is assumed to provide at least as much clinical benefit as IV pamidronate. This analysis included referenced NHS costs for drug acquisition and administration (pharmacy preparation, disposables and nurse time required for infusions/IV administration) and compared IV ibandronate to the "average" use of IV pamidronate-45 mg infused at 20 mg/hour. Due to the range of doses and infusion types used for IV pamidronate, sensitivity analyses were conducted. RESULTS: Ibandronate is costsaving on acquisition (£18/patient/year) and particularly on administration (£407/patient/year). The total cost-saving associated with a switch from pamidronate to ibandronate is approximately £425/patient/year and driven primarily by lower administration costs. Under sensitivity analysis, ibandronate remains cost-saving even when the comparator is generic 30 mg pamidronate, pamidronate is infused at the maximum rate, or when nurses manage several patients' infusions simultaneously. CONCLUSIONS: Ibandronate IV injection is cost-saving for the NHS compared to IV pamidronate infusion, under a range of realistic scenarios. When this finding is considered alongside IV ibandronate's evidence base and licence for PMO, it is concluded that ibandronate IV injection clearly offers value for money.
POS7

COST-EFFECTIVENESS OF RISEDRONATE VS. GENERIC ALENDRONATE: CONSIDERATION OF CALCIUM SUPPLEMENTS
Moehrke W 1 , Pasquale M 2 , Moeller G 1 1 Procter & Gamble Pharmaceuticals, Schwalbach a.Ts, Germany, 2 Procter & Gamble Pharmaceuticals, Mason, OH, USA OBJECTIVES: Treatment of post-menopausal osteoporosis with bisphosphonates should be supplemented by adequate amounts of calcium. The objective of this analysis was to assess the costeffectiveness of the combination package of risedronate plus calcium compared to generic alendronate and calcium supplements in high-risk osteoporotic patients in Germany. METHODS: A validated model (Tosteson, 2001 ) was used to estimate the impact of therapy on hip and vertebral fractures, costs, and quality adjusted life years (QALYs). The analysis included women 70 years with a BMD T-Score of <−2.5 and a history of vertebral fracture, treated over 3 years. The model further simulated downstream costs and QALYs for a 10-year period. Country-specific data included general population mortality, hip and hospitalized vertebral fracture rates, fracture costs, and annual drug costs (risedronate plus calcium €547.76; generic alendronate €411.23; calcium €59.50). Hip and vertebral fracture reductions for risedronate were 60% (McClung, Geusens, Miller, 2001) and 49% (Reginster, Minne, Sorenson, 2000) respectively; and for alendronate were 51% and 47% (Black, Cummings, Karpf, 1996) respectively. RESULTS: In a cohort of 1000 postmenopausal women with 3 years of treatment the model predicted the following costs of €8.42M versus €8.40M, total hip and hospitalized vertebral fractures of 140 versus 143 and QALYs of 6168 versus 6164 for risedronate plus calcium and generic alendronate plus calcium, respectively. Risedronate plus calcium was more cost-effective than generic alendronate plus calcium, with a cost per fracture averted of €8764 and a cost per QALY gained of €8698. CONCLUSIONS: The analysis favors the adoption of risedronate plus calcium therapy for the treatment of postmenopausal osteoporosis compared to generic alendronate plus calcium.
